Title

肝癌自體抗原之鑑定與生物標記開發

Translated Titles

Identification of Autoantigens as Biomarkers in Hepatocellular Carcinoma

DOI

10.6342/NTU.2010.02828

Authors

施函君

Key Words

肝癌 ; 甲型胎兒蛋白 ; 腫瘤相關抗原 ; hnRNP L ; Illumina Veracode Carboxyl Beads ; Hepatocellular Carcinoma ; Alpha-Fetoprotein ; Tumor-Associated Antigen ; hnRNP L ; Illumina Veracode Carboxyl Beads

PublicationName

臺灣大學生物化學暨分子生物學研究所學位論文

Volume or Term/Year and Month of Publication

2010年

Academic Degree Category

碩士

Advisor

周綠蘋

Content Language

繁體中文

Chinese Abstract

肝癌 (hepatocellular carcinoma, HCC) 是台灣最常見的惡性腫瘤之一,位居台灣十大癌症死亡原因的前二位。目前肝癌血液檢查的診斷方式是偵測甲型胎兒蛋白 (alpha-fetoprotein, AFP) 的含量,若 AFP 的量超過 20 ng/mL 則可能罹患肝癌,然而在慢性肝炎病人中肝細胞再生時 AFP 也會增高表特異性不佳,此外腫瘤小於兩公分的肝癌病人 AFP 的靈敏度只有 43 %,顯示 AFP 在肝癌早期無法成為有效的檢測工具,因此尋找有效的生物標記作為診斷肝癌早期的指標是非常重要的。腫瘤細胞異常表現的蛋白質會引發身體的免疫反應產生自體抗體 (autoantibody),這些引起免疫反應的蛋白質稱為腫瘤相關抗原 (tumor-associated antigen, TAA),過去利用血清蛋白質體分析 (serological proteome analysis, SERPA) 鑑定到數個可能為肝癌 TAA 的蛋白質,挑選肝癌血清反應較高的蛋白質 hnRNP L、DEAD、lamin A/C 與 hnRNP B1 作確認。由一維電泳免疫轉染法發現肝癌病人血清與 hnRNP L 及 DEAD 反應頻率較高,分別為 64.5 % 和 67.7 %,與正常人、B型肝炎帶原者及肝硬化病人血清比較都有顯著差異,p value 小於 0.01。肝癌病人血清與 hnRNP L 或 DEAD 有反應的頻率是 85.5 % 特異性為 45 %。肝癌病人血清與 hnRNP L 和 DEAD 同時有反應的頻率是 46.8 % 特異性為 95 %。利用酵素連結免疫吸附分析 (enzyme-linked immunosorbent assay, ELISA) 發現肝癌病人血清對具有抗原決定部位 (epitope) 之短肽 hnRNP L 反應頻率較好,與其他三組血清比較 p value 小於 0.01。為了實行多重生物標記偵測,初步利用 Illumina Veracode Carboxyl Beads 作為 multiplexed protein assay,發現肝癌病人血清與短肽 hnRNP L 反應的頻率是 67.0 %,與其他三組血清比較 p value 小於 0.01。這些結果顯示 hnRNP L 與 DEAD 可為肝癌的 TAA,且短肽 hnRNP L 較適合作為肝癌生物標記。

English Abstract

Hepatocellular carcinoma (HCC), one of malignant tumors in Taiwan, is the top two causes of cancer death. Serum alpha-fetoprotein (AFP), at a cutoff value of 20 ng/mL, is currently the most widely used tumor marker for diagnosis of HCC. However, some patients with cirrhosis or hepatic inflammation can have an elevated AFP. Furthermore, sensitivity of AFP decreases to 43 % when tumor diameter is less than 2 cm. It shows that AFP can’t be an effective early detection tool for HCC so it’s important to find valid biomarkers as early indicators of HCC. Abnormal proteins, also known as tumor-associated antigens (TAAs), expressed by tumor cells would trigger the immune response to generate autoantibodies. Many TAAs were identified by serological proteome analysis (SERPA) and four proteins, hnRNP L, DEAD, lamin A/C, and hnRNP B1, were selected to do further research. Using 1D immunoblot, hnRNP L and DEAD were identified as HCC-related antigens, showing a higher seropositivity, 64.5 % and 67.7 %, in HCC patients than in controls, HBV-carrier, or cirrhosis patients. In addition, combination of hnRNP L or DEAD showed a high seropositivity, 85.5 %, in HCC patients, and specificity is 45 %. Combination of hnRNP L and DEAD showed a high specificity, 95 %, and sensitivity is 46.8 %. It also showed that the peptide epitope of hnRNP L had a higher seropositivity in HCC patients than other three groups by enzyme linked immunosorbent assay (ELISA). For detecing multiple biomarkers, Illumina Veracode Carboxyl Beads as multiplexed protein assay was used to screen the peptide of hnRNP L, and results indicated that the seropositivity is 67 % in HCC patients. In brief, hnRNP L and DEAD may be HCC-related antigens, and the epitope of hnRNP L is better to be a biomarker for early diagnosis of HCC.

Topic Category 醫藥衛生 > 基礎醫學
醫學院 > 生物化學暨分子生物學研究所
Reference
  1. 2. El-Serag, H. B., and Rudolph, L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132, 2557-2576.
    連結:
  2. 3. Hussain, S. P., Schwank, J., Staib, F., Wang, X. W., and Harris, C. C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007, 26, 2166-2176.
    連結:
  3. 4. Seeger, C., and Mason, W. S. Hepatitis B virus biology. Microbiol. Mol. Biol. R. 2000, 64, 51-68.
    連結:
  4. 5. Fung, J., Lai, C. L., and Yuen, M. F. Hepatitis B and C virus-related carcinogenesis. Clin. Microbiol. Infec. 2009, 15, 964-970.
    連結:
  5. 6. El-Serag, H. B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002, 36, S74-S83.
    連結:
  6. 7. Fattovich, G., Stroffolini, T., Zagni, I., and Donato, F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 2004, 127, S35-S50.
    連結:
  7. 8. Jackson, P. E., and Groopman, J.D. Aflatoxin and liver cancer. Best Pract. Res. Cl. Ga. 1999, 13, 545-555.
    連結:
  8. 9. Morgan, T. R., Mandayam, S., and Jamal, M. M. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004, 127, S87-S96.
    連結:
  9. 10. Naccarato, R., and Farinati, F. Hepatocellular-carcinoma, alcohol, and cirrhosis – facts and hypothesis. Digest. Dic. Sci. 1991, 36, 1137-1142.
    連結:
  10. 11. Donato, F., Tagger, A., Gelatti, U., Parrinello, G., Boffetta, P., Albertini, A., Decarli, A., Trevisi, P., Ribero, M. L., Martelli, C., Porru, S., and Nardi, G. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am. J. Epidemiol. 2002, 155, 323-331.
    連結:
  11. 12. Giannitrapani, L., Soresi, M., La Spada, E., Cervello, M., D'Alessandro, N., and Montalto, G.. Sex hormones and risk of liver tumor. Ann. Ny. Acad. Sci. 2006, 1089, 228-236.
    連結:
  12. 13. Malaguarnera, G., Giordano, M., Paladina, I., Berretta, M., Cappellani, A., and Malaguarnera, M. Serum markers of hepatocellular carcinoma. Dig. Dis. Sci. 2010.
    連結:
  13. 14. Gomaa, A. I., Khan, S. A., Leen, E. L. S., Waked, I., and Taylor-Robinson, S. D. Diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 2009, 15, 1301-1314.
    連結:
  14. 15. Squillante, M. M., Cellerinoc, C., Clementea, R., Tontia, P., Giuliania, A., Fusillib, S., Siena, D. A., Pompili, M., and Caturelli, E. Pulsed Doppler US diagnosis of hepatocellular carcinoma and other liver focal lesions. Eur. J. Ultrasound. 1995, 2, 269-272.
    連結:
  15. 16. Zhao, H., Yao, J. L., Wang, Y., and Zhou, K. R. Detection of small hepatocellular carcinoma: Comparison of dynamic enhancement magnetic resonance imaging and multiphase multirow-detector helical CT scanning. World J. Gastroenterol. 2007, 13, 1252-1256.
    連結:
  16. 17. Schölmerich, J., and Schacherer, D. Diagnostic biopsy for hepatocellular carcinoma in cirrhosis: useful, necessary, dangerous, or academic sport? Gut. 2010.
    連結:
  17. 18. Caturelli, E., and de Sio, I. Biopsy diagnosis of hepatocellular carcinoma. Hepatology. 2008, 47, 2145-2145.
    連結:
  18. 19. Toniolo, P., Boffetta, P., Shuker, D. E. G., Rothman, N., Hulka, B., and Pearce, N. Application of biomarkers in cancer epidemiology. Epidemiology. 1998, 9, 681-682.
    連結:
  19. 20. Pepe, M. S., Etzioni, R., Feng, Z. D., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, and M., Yasui, Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer I. 2001, 93, 1054-1061.
    連結:
  20. 22. Ian, J., and Robert, C. B. The CA 125 tumour-associated antigen: a review of the literature. Hum. Reprod. 1989, 4, 1-12.
    連結:
  21. 23. Partin, A. W., Catalona, W. J., Southwick, P. C., Subong, E. N. P., Gasior, G. H., and Chan, D. W. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology. 1996, 48, 55-61.
    連結:
  22. 24. Dnistrian, A. M., Schwartz, M. K., Greenberg, E. J., Smith, C. A., and Schwartz, D. C. CA 15-3 and carcinoembryonic antigen in the clinical-evaluation of breast-cancer. Clin. Chim. Acta. 1991, 200, 81-93.
    連結:
  23. 25. Yoon, S. K. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology. 2008, 51, 34-41.
    連結:
  24. 26. Li, D., Mallory, T., and Satomura, S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin. Chim. Acta. 2001, 313, 15-19.
    連結:
  25. 28. Daniele, B., Bencivenga, A., Megna, A. S., and Tinessa, V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004, 127, S108-S112.
    連結:
  26. 29. Wang, C. S., Lin, C. L., Lee, H. C., Chen, K. Y., Chiang, M. F., Chen, H. S., Lin, T. J., and Liao, L. Y. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J. Gastroenterol. 2005, 11, 6115-6119.
    連結:
  27. 30. Grazi, G. L., Mazziotti, A., Legnani, C., Jovine, E., Miniero, R., Gallucci, A., Palareti, G., and Gozzetti, G. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transplant. Sur. 1995, 1, 249-255.
    連結:
  28. 31. Zhang, J. Y., and Tan, E. M. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev. Mol. Diagn. 2010, 10, 321-328.
    連結:
  29. 32. Tan, E. M., and Zhang, J. Y. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol. Rev. 2008, 222, 328-340.
    連結:
  30. 33. Hung, C. F., Wu, T. C., Monie, A., and Roden, R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol. Rev. 2008, 222, 43-69.
    連結:
  31. 34. Desmetz, C., Maudelonde, T., Mange, A., and Solassol, J. Identifying autoantibody signatures in cancer: a promising challenge. Expert Rev. Mol. Diagn. 2009, 6, 377-386.
    連結:
  32. 35. Diamandis, E. P. Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. J. Natl. Cancer I. 2004, 96, 353-356.
    連結:
  33. 36. Poon, T. C. W., and Johnson, P. J. Proteome analysis and its impact on the discovery of serological tumor markers. Clin. Chim. Acta. 2001, 313, 231-239.
    連結:
  34. 37. Desmetz, C., Cortijo, C., Mange, A., and Solassol, J. Humoral response to cancer as a tool for biomarker discovery. J. Proteomics. 2009, 72, 982-988.
    連結:
  35. 38. Tan, H. T., Low, J., Lim, S. G., and Chung, M. C. M. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009, 276, 6880-6904.
    連結:
  36. 39. Chen, Y., Zhou, Y. S., Qiu, S. M., Wang, K. J., Liu, S. W., Peng, X. X., Li, J. F., Tan, E. M., and Zhang, J. Y. Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett. 2010, 289, 32-39.
    連結:
  37. 41. Himoto, T., Kuriyama, S., Zhang, J. Y., Chan, E. K. L., Kimura, Y., Masaki, T., Uchida, N., Nishioka, M., and Tan, E. M. Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int. J. Oncol. 2005, 27, 1079-1085.
    連結:
  38. 42. Garcia, H. H., Harrison, L. J. S., Parkhouse, R. M. E., Montenegro, T., Martinez, S. M., Tsang, V. C. W., and Gilman, R. H. A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis. T. Roy. Soc. Trop. Med. H. 1998, 92, 411-414.
    連結:
  39. 45. Hernandez-Vargas, H., Lambert, M. P., Le Calvez-Kelm, F., Gouysse, G., McKay-Chopin, S., Tavtigian, S. V., Scoazec, J. Y., and Herceg, Z. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS ONE. 2010, 5, e9749.
    連結:
  40. 46. Du, R., Tantisira, K., Carey, V., Bhattacharya, S., Metje, S., Kho, A. T., Klanderman, B. J., Gaedigk, R., Lazarus, R., Mariani, T. J., Leeder, S., and Weiss, S. T. Platform dependence of inference on gene-wise and gene-set involvement in human lung development. BMC Bioinfomatics. 2009, 10, 189.
    連結:
  41. 47. Krecic, A. M., and Swanson, M. S. hnRNP complexes: composition, structure, and function. Curr. Opin. Cell Biol. 1999, 11, 363-371.
    連結:
  42. 48. Dreyfuss, G., Matunis, M. J., Pinolroma, S., and Burd, C. G. hnRNP proteins and the biogenesis of mRNA. Annu. Rev. Biochem. 1993, 62, 289-321.
    連結:
  43. 49. Hahn, B., Kim, Y. K., Kim, J. H., Kim, T. Y., and Jang, S. K. Heterogeneous nuclear ribonucleoprotein L interacts with the 3 ' border of the internal ribosomal entry site of hepatitis C virus. J. Virol. 1998, 72, 8782-8788.
    連結:
  44. 50. Shih, S. C., and Claffey, K. P. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J. Biol. Chem. 1999, 274, 1359-1365.
    連結:
  45. 51. Hamilton, B. J., Nichols, R. C., Tsukamoto, H., Boado, R. J., Pardridge, W. M., and Rigby, W. F. C. hnRNP A2 and hnRNP L bind the 3 ' UTR of glucose transporter 1 mRNA and exist as a complex in vivo. Biochem. Bioph. Res. Co. 1999, 261, 646-651.
    連結:
  46. 52. Hui, J., Stangl, K., Lane, W. S., and Bindereif, A. hnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat. Struct. Biol. 2003, 10, 33-37.
    連結:
  47. 53. Siapka, S., Patrinou-Georgoula, M., Vlachoyiannopoulos, P. G., and Guialis, A. Multiple specificities of autoantibodies against hnRNP A/B proteins in systemic rheumatic diseases and hnRNP L as an associated novel autoantigen. Autoimmunity. 2007. 40, 223-233.
    連結:
  48. 54. Yang, F., Chen, I. H., Xiong, Z. Y., Yan, Y., Wang, H., and Yang, X. F. Model of stimulation-responsive splicing and strategies in identification of immunogenic isoforms of tumor antigens and autoantigens. Clin. Immunol. 2006, 121, 121-133.
    連結:
  49. 55. Gustafson, E. A., and Wessel, G. M. DEAD-box helicases: Posttranslational regulation and function. Biochem. Bioph. Res. Co. 2010, 395, 1-6.
    連結:
  50. 58. 中國醫藥大學附設醫院肝病中心-網站
    連結:
  51. 1. De Medicina, F., de Gastrohepatología, G., and de Antioquia, U. Pathology of liver tumors. Suplemento Iatreia. 2007, 20, S16-S17.
  52. 21. Sturgeon, C. Practice guidelines for tumor marker use in the clinic. Clin. Chem. 2002, 48, 1151-1159.
  53. 27. Nakatsura, T., Yoshitake, Y., Senju, S., Monji, M., Komori, H., Motomura, Y., Hosaka, S., Beppu, T., Ishiko, T., Kamohara, H., Ashihara, H., Katagiri, T., Furukawa, Y., Fujiyama, S., Ogawa, M., Nakamura, Y., and Nishimura, Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Bioph. Res. Co. 2003, 306, 16-25.
  54. 40. Quinn, J., Gratalo, D., Haden, K., and Moon, J. Accurate multiplex cytokine assay developed with VeraCode technology. 2008.
  55. 43. Bei, R., Budillon, A., Reale, M. G., Capuano, G., Pomponi, D., Budillon, G., Frati, L., and Muraro, R. Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. Cancer Res. 1999, 59, 5471-5474.
  56. 44. Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Tredaniel, J., Hirsch, A., Defromentel, C. C., Preudhomme, C., Fenaux, P., Fournier, G., Mangin, P., Laurentpuic, P., Pelletier, G., Schlumberger, M., Desgrandchamps, F., Leduc, A., Peyrat, J. P., Janin, N., Bressac, B., and Soussi, T. Analysis of p53 antibodies in patients with various cancers define B-Cell epitopes of human p53: Distribution on primary structure and exposure on protein surface1. Cancer Res. 1993, 53, 5872-5876.
  57. 56. Botlagunta, M., Vesuna, F., Mironchik, Y., Raman, A., Lisok, A., Winnard, P., Mukadam, S., Van Diest, P., Chen, J. H., Farabaugh, P., Patel, A. H., and Raman, V. Oncogenic role of DDX3 in breast cancer biogenesis. Oncogene. 2008, 27, 3912-3922.
  58. 57. 林敬斌醫師-肝癌在台灣